Combined Rituximab and Daratumumab Treatment in Difficult-to-Treat Nephrotic Syndrome Cases
暂无分享,去创建一个
G. Ghiggeri | G. Caridi | P. Cravedi | A. Magnasco | G. Candiano | M. Bruschi | E. La Porta | Xhuliana Kajana | Sofia Bin | Carolina Bigatti | Andrea Angeletti | Francesca Lugani | Enrico E. Verrina | Sonia Spinelli
[1] G. Ghiggeri,et al. Biologics in steroid resistant nephrotic syndrome in childhood: review and new hypothesis-driven treatment , 2023, Frontiers in immunology.
[2] B. Rovin,et al. Natural Antibody and Complement Activation Characterize Patients with Idiopathic Nephrotic Syndrome. , 2021, American journal of physiology. Renal physiology.
[3] M. Schnitzler,et al. Immunosuppression Considerations for Older Kidney Transplant Recipients , 2021, Current Transplantation Reports.
[4] J. Myers,et al. Association of physical function and performance with peak VO2 in elderly patients with end stage kidney disease , 2021, Aging Clinical and Experimental Research.
[5] C. McCulloch,et al. Sex Disparity in Deceased-Donor Kidney Transplant Access by Cause of Kidney Disease. , 2021, Clinical journal of the American Society of Nephrology : CJASN.
[6] M. Stedman,et al. Toward telemedicine‐compatible physical functioning assessments in kidney transplant candidates , 2020, Clinical transplantation.
[7] J. Hogan,et al. A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome , 2020, Pediatric Nephrology.
[8] M. Stedman,et al. Physical Performance Testing in Kidney Transplant Candidates at the Top of the Waitlist. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] K. Khush,et al. To kidney or not to kidney: Applying lessons learned from the simultaneous liver‐kidney transplant policy to simultaneous heart‐kidney transplantation , 2020, Clinical transplantation.
[10] K. Johansen,et al. An overview of frailty in kidney transplantation: measurement, management and future considerations. , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[11] W. Kim,et al. Defining a Willingness-to-transplant Threshold in an Era of Organ Scarcity: Simultaneous Liver–kidney Transplant as a Case Example , 2020, Transplantation.
[12] K. Lentine,et al. Implications of Frailty for Peritransplant Outcomes in Kidney Transplant Recipients , 2019, Current Transplantation Reports.
[13] A. Bagga,et al. Management of steroid-resistant nephrotic syndrome in children and adolescents. , 2018, The Lancet. Child & adolescent health.
[14] Andrew A. Li,et al. Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era , 2018, Diseases.
[15] R. Parekh,et al. Idiopathic nephrotic syndrome in children , 2018, The Lancet.
[16] Donghee Kim,et al. Long-term Patient and Graft Survival of Kidney Transplant Recipients With Hepatitis C Virus Infection in the United States , 2017, Transplantation.
[17] Ming-hui Zhao,et al. Clinical Significance of IgM and C3 Glomerular Deposition in Primary Focal Segmental Glomerulosclerosis. , 2016, Clinical journal of the American Society of Nephrology : CJASN.
[18] P. Ravani,et al. Long-term Kidney Transplant Outcomes in Primary Glomerulonephritis: Analysis From the ERA-EDTA Registry , 2016, Transplantation.
[19] C. Lenihan,et al. The consequences of chronic kidney disease mislabeling in living kidney donors. , 2014, Mayo Clinic proceedings.
[20] Jane C. Tan,et al. A new clinical prediction tool for 5-year kidney transplant outcome. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[21] N. Kambham,et al. Acute transplant glomerulopathy with monocyte rich infiltrate. , 2013, Transplant immunology.
[22] D. Gipson,et al. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO , 2013, Pediatric Nephrology.
[23] A. Edefonti,et al. Rituximab in children with resistant idiopathic nephrotic syndrome. , 2012, Journal of the American Society of Nephrology : JASN.
[24] B. Daniel,et al. Multiple renal arteries and non-contrast magnetic resonance angiography in transplant renal artery stenosis , 2012, Clinical kidney journal.
[25] S. Busque,et al. Living donor evaluation and exclusion: the Stanford experience , 2011, Clinical transplantation.
[26] G. Chertow,et al. Cautious optimism concerning long-term safety of kidney donation. , 2009, The New England journal of medicine.
[27] P. Tummala,et al. Circulating growth hormone binding protein levels and mononuclear cell growth hormone receptor expression in uremia. , 2006, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.
[28] H. Valantine,et al. Validation of a screening protocol for identifying low‐risk candidates with type 1 diabetes mellitus for kidney with or without pancreas transplantation , 2006, Clinical transplantation.
[29] S. Busque,et al. Preoperative renal volumes as a predictor of graft function in living donor transplantation. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[30] E. Alfrey,et al. Dual-Kidney Transplantation with Organs from Expanded Criteria Donors: A Long-Term Follow-Up , 2004, Transplantation.
[31] H. Yeh,et al. Noradrenergic potentiation of cerebellar Purkinje cell responses to GABA: cyclic AMP as intracellular intermediary , 1996, Neuroscience.